1. Home
  2. OCGN vs CCII Comparison

OCGN vs CCII Comparison

Compare OCGN & CCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCGN
  • CCII
  • Stock Information
  • Founded
  • OCGN 2013
  • CCII 2024
  • Country
  • OCGN United States
  • CCII United States
  • Employees
  • OCGN N/A
  • CCII N/A
  • Industry
  • OCGN Biotechnology: Biological Products (No Diagnostic Substances)
  • CCII
  • Sector
  • OCGN Health Care
  • CCII
  • Exchange
  • OCGN Nasdaq
  • CCII Nasdaq
  • Market Cap
  • OCGN 321.7M
  • CCII 359.1M
  • IPO Year
  • OCGN N/A
  • CCII 2025
  • Fundamental
  • Price
  • OCGN $1.52
  • CCII $10.40
  • Analyst Decision
  • OCGN Strong Buy
  • CCII
  • Analyst Count
  • OCGN 2
  • CCII 0
  • Target Price
  • OCGN $7.00
  • CCII N/A
  • AVG Volume (30 Days)
  • OCGN 5.9M
  • CCII 155.6K
  • Earning Date
  • OCGN 11-05-2025
  • CCII 01-01-0001
  • Dividend Yield
  • OCGN N/A
  • CCII N/A
  • EPS Growth
  • OCGN N/A
  • CCII N/A
  • EPS
  • OCGN N/A
  • CCII N/A
  • Revenue
  • OCGN $4,754,000.00
  • CCII N/A
  • Revenue This Year
  • OCGN N/A
  • CCII N/A
  • Revenue Next Year
  • OCGN N/A
  • CCII N/A
  • P/E Ratio
  • OCGN N/A
  • CCII N/A
  • Revenue Growth
  • OCGN N/A
  • CCII N/A
  • 52 Week Low
  • OCGN $0.52
  • CCII $10.07
  • 52 Week High
  • OCGN $1.90
  • CCII $10.47
  • Technical
  • Relative Strength Index (RSI)
  • OCGN 48.14
  • CCII N/A
  • Support Level
  • OCGN $1.47
  • CCII N/A
  • Resistance Level
  • OCGN $1.65
  • CCII N/A
  • Average True Range (ATR)
  • OCGN 0.11
  • CCII 0.00
  • MACD
  • OCGN -0.03
  • CCII 0.00
  • Stochastic Oscillator
  • OCGN 13.51
  • CCII 0.00

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares

Cohen Circle Acquisition Corp II is a blank check company.

Share on Social Networks: